Page 1

Schizophrenia Drugs Market Size, Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026 Sample PDF

Get Discount

Published Date: April 2019

Region: Global

Report Format: PDF

Base Year: 2018

Fortune Business Insights Pvt Ltd.

Buy Now


Schizophrenia Drugs Market Size, Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026 Report Highlights: The increasing prevalence of chronic and mental disorder is a key factor expected to enable growth in the global schizophrenia drugs market, says Fortune Business Insights in a report, titled “Schizophrenia Drugs Market Size, Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026.� The global schizophrenia drugs market was valued at USD 6.75 Billion in 2018 and is projected to reach USD 9.48 Billion by 2026, exhibiting a CAGR of 4.3% during the forecast period.

The report published by Fortune Business Insights provides an exclusive overview of the schizophrenia drugs industry. The report is put together after extensive research and study by the top analysts offers key insights into the global schizophrenia drugs market to help businesses gain a competitive advantage and flourish rapidly. In-depth information on recent advancements and innovations are all present in the report. Fortune Business Insights Pvt Ltd.


Schizophrenia Drugs Market Size, Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026 Rising Awareness About Mental Disorders Will Boost Growth According to Fortune Business Insights, the increasing cases of mental disorders such as schizophrenia will uplift the global schizophrenia drugs market shares. The surge in medical interventions for the treatment of major mental disorders will enable growth in the global schizophrenia drugs market during the forecast period. Furthermore, the rising emphasis on mental illness and mental health in emerging nations will boost the global schizophrenia drugs market revenue during the forecast period. Launch Of REXULTI Tablets Will Propel Growth Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company headquartered in Tokyo launched REXULTI Tablets (chemical name is brexpiprazole) in 1 mg and 2 mg tablets for the treatment of schizophrenia in patients. Based on the efficacy of REXULTI in the treatment of schizophrenia, it is included in the Japanese National Health Insurance Drug Price List. The launch of REXULTIÂŽ Tablets will favor growth to the global schizophrenia drugs market owing to the presence of a novel compound in the tablets. REXULTI Tablets will be marketed to healthcare institutions across Japan to treat patients with mental disorders. Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/schizophrenia-drugs-market-101531 Fortune Business Insights Pvt Ltd.


Schizophrenia Drugs Market Size, Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026 Furthermore, according to the report published by Fortune Business Insights on the basis of treatment outlook the global schizophrenia drugs market is segmented into oral and injectable. Injectedbale based treatment is predicted to generate maximum revenue owing to the prevention of relapses and also the irreparable cognitive and neurological damages to the patients. Top Players Mentioned: Fortune Business Insights profiles a few of the companies operating in the global Schizophrenia Drugs Market H. Lundbeck A/S Otsuka Pharmaceutical Co., Ltd. Janssen Pharmaceuticals, Inc. Eli Lilly and Company AstraZeneca ALLERGAN Vanda Pharmaceuticals Inc. Sumitomo Dainippon Pharma Co., Ltd. Fortune Business Insights Pvt Ltd.


Schizophrenia Drugs Market Size, Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2019-2026 About Us: Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. Phone: US: +1 424 253 0390 UK: +44 2071 939123 APAC: +91 744 740 1245 Email: sales@fortunebusinessinsights.com Fortune Business Insights Pvt Ltd.

Profile for avani.sonwane29

Schizophrenia Drugs Market to surge at 4.3% CAGR and Hit USD 9.48 Billion by 2026  

Schizophrenia Drugs Market 2019 Fortune Business Insights report provides key analysis on the market status of the Schizophrenia Drugs manuf...

Schizophrenia Drugs Market to surge at 4.3% CAGR and Hit USD 9.48 Billion by 2026  

Schizophrenia Drugs Market 2019 Fortune Business Insights report provides key analysis on the market status of the Schizophrenia Drugs manuf...